It has been a major week in the stem cell industry, with partnerships, licensing deals, and pre-clinical findings recently announced. Check out the latest coverage below. [Read more…]
BrainXell Enters Agreement for iPSC Patent Technology with iPS Academia Japan
BrainXell and iPS Academia Japan have announced a global licensing agreement covering components of the induced pluripotent stem (iPS) cell patent portfolio owned by iPS Academia Japan. Under the terms of the non-exclusive agreement, BrainXell will be able to commercialize iPS-derived cells and offer related services to it customers. The value and terms of the agreement have not been announced.
The iPS cell patent portfolio being licensed by BrainXell has resulted from work by Professor Shinya Yamanaka at the Center for iPS Cell Research and Application (CiRA) at Kyoto University.
BrainXell is a a stem cell company based in Madison, Wisconsin, while iPS Academia Japan is based in Kyoto, Japan. BrainXell specializes in using iPSC-derived neural cells for use on a custom basis to pharmaceutical companies for research programs. iPS Academia Japan is an affiliate of Kyoto University, a major research university in Japan. Kyoto University is also a global leader in developing induced pluripotent stem cell (iPSC) technologies.
BrainXell is making brain cells by the billions. @UWMadison spinoff sells neural cells to drug researchers via @UWMadScience. pic.twitter.com/zuw6l0EMec
— CIRM (@CIRMnews) November 1, 2016
The role of iPS Acadmia Japan is to commercialize the patents and other IP created by Kyoto University and other universities and research institutions developing iPSC technologies.
According to Zhong-Wei Du, Chief Technology Officer of BrainXell, “BrainXell is now enabled through this iPS cell technology license and its Wisconsin Alumni Research Foundation (WARF) license on neural stem cell differentiation to provide a broad range of neural cells for research at numerous institutions and biopharmaceutical companies.”
To learn more, view the license announcement.
Cynata and FUJIFILM Sign Non-binding Development and Commercialisation Term Sheet
Melbourne, Australia; 5 September 2016 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016. [Read more…]
Cynata Shares Jump as Japan’s FUJIFILM Negotiates Deal to Commercialize Cymerus™ Stem Cell Technology
Cynata Therapeutics (ASX: CYP) has executed a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead product, CYP-001. CYP-001 is an induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSC) product that is anticipated to be the first allogeneic iPSC product to enter a clinical trial.
Dominance of Cellular Dynamics International (CDI) within iPSC Marketplace
Cellular Dynamics International (CDI), a FUJIFILM company, is the largest provider of induced pluripotent stem cell (iPSC) products worldwide. iPSCs are a type of laboratory made stem cell that has significant potential for use within regenerative medicine.
Theoretically, iPSCs have the potential to treat a wide range of diseases, including diabetes, heart diseases, autoimmune diseases, neural decline and more. iPSCs are also being widely implemented for use in drug development and discovery, as well as toxicology screening and personalized medicine.
In this article:
- Life Science Business Unit
- iPSC Market Competitors
- Cellular Dynamics International, Owned by Fujifilm Holdings
- Cellular Dynamics and Shinya Yamanaka
- Cellular Dynamics International Product Licenses
- An Important Player in Stem Cell Research and Therapy
- Use of iPSCs in Drug Development and Discovery
- CDI’s Acquisition by FUJIFILM Holdings Corporation
- The Advantage of Cellular Dynamics’ Fujifilm Acquisition
- Where Will CDI Focus iPSC Cell Production Technology?
Cellular Dynamics International and iPSC Therapy
Since September 2016, Cellular Dynamics International (CDI) has been divided into two business units, a Therapeutics Business Unit and a Life Science business unit. CDI’s Therapeutics business unit is focused on developing induced pluripotent stem cell (iPSC) based therapies for ocular, cardiac, neural and oncology applications. In contrast, CDI’s Life Science business unit is focused on developing the research products side of the business.
iPSC Market Competitors
In addition to CDI, there are many other companies and organizations that are involved with the development of induced pluripotent stem cell (iPSC) therapies, including but not limited to:
- Ocata Therapeutics
- RIKEN
- Kyoto University and CiRA
- Fate Therapeutics
- Megakaryon Corporation
- Cynata Therapeutics
There are also a number of companies specializing in iPSC product development, including:
- Allele Biotechnology
- ALSTEM Bio
- Applied Biological Materials (ABM)
- Applied StemCell
- Axol Bioscience
- BrainXell
- Cell Applications
- Cellular Dynamics International (a Fujifilm Company)
- EMD Millipore
- Minerva Biotechnologies
- Ncardia (formed through merger of Axiogenesis and Pluriomics)
- Neucyte
- Pluricell Biotech
- REPROCELL
- Sigma Aldrich (provides 350 iPSC lines through partnership with EBiSC)
- STEMCELL Technologies
- Stemgent (iPS Cell Business Unit owned by ReproCELL)
- Takara Bio
- Tempo Bioscience
- Thermo Fisher Scientific
- xCell Sciences
- And others
Fujifilm Cellular Dynamics Inc
Cellular Dynamics International is one of the most important market participants in the iPSC sector, because of its dominance in both iPSC therapies and life science tools.
- « Previous Page
- 1
- …
- 236
- 237
- 238
- 239
- 240
- …
- 307
- Next Page »